Phase 1 N=15 Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis
Pulmonary Sarcoidosis · Lung Function
Primary: Change in Absolute FVC From Baseline to Post Completion of 8 Weeks of Antibiotic Therapy. — 2.61 liters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study
Sarcoidosis
Primary: Forced Vital Capacity (FVC) — 0.07; -0.07 liters
Phase 2 N=55 Atorvastatin to Treat Pulmonary Sarcoidosis
Sarcoidosis, Pulmonary
Primary: The Steroid Sparing Period — 301; 257 days
Phase 2 N=40 Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis
Pulmonary Sarcoidosis
Primary: Change Between Baseline and Week 24 in Pulmonary Function as Measured by Spirometry — -1.90; 0.52 Percent Predicted Forced Vital Capacity
Phase 3 N=12 Tadalafil for Sarcoidosis Associated Pulmonary Hypertension
Pulmonary Hypertension
Primary: 6 Minute Walk Distance — 419.1; 418.1; 436.5; 377.1 meters — p=0.68
Phase 2 N=97 Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis
Sarcoidosis; Antimycobacterial Therapy
Primary: Change in Percent Predicted Absolute Forced Vital Capacity (FVC) in Participants With Pulmonary Sarcoidosis, Comparing Baseline With Performance After Completion of 16…
N/A N=17 The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
Pulmonary Sarcoidosis
Primary: Bronchoalveolar Lavage (BAL) and Peripheral Blood Mononuclear Cells (PBMC) TNF-α Levels — 40767; 39938; 45176; 25671 pg/ml
Phase 2 N=29 Trial of Antimycobacterial Therapy in Sarcoidosis
Sarcoidosis
Primary: Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions — -8.4…
Phase 4 N=55 Acthar Gel in Participants With Pulmonary Sarcoidosis
Sarcoidosis, Pulmonary
Primary: DBT: Number of Participants in Each Category of Assessment Based on Forced Vital Capacity (FVC), a Pulmonary Function Test Parameter at Week 24 — 10; 7; 12; 12…
Phase 2 N=62 Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
Pulmonary Sarcoidosis
Primary: Change in Percent Predicted FVC From Baseline to 16 Weeks of Treatment — -0.48; 1.02 Percent predicted — p=0.1804
Phase 1 N=5 Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis
Sarcoidosis, Pulmonary · Sarcoidosis Lung · Sarcoidosis
Primary: Number of Participants With 50% Reduction in Corticosteroid Requirement — 3 Participants
Phase 2 N=142 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Scleroderma · Interstitial Lung Disease
Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24
Phase 2 N=173 A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
Sarcoidosis
Primary: Change From Baseline in Percent-predicted Forced Vital Capacity (FVC) at Week 16 — 2.02; 1.15; -0.15 percent of predicted FVC — p=0.543
N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
Phase 2 N=17 Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis
Cardiac Sarcoidosis
Primary: Change in Inflammation Marker — -43; 7 mg/L
Phase 3 N=158 Scleroderma Lung Disease
Lung Diseases · Pulmonary Fibrosis · Systemic Scleroderma
Primary: Forced Vital Capacity — 66.6; 65.6 % of predicted
Phase 2 N=37 Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
Pulmonary Sarcoidosis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 10; 8; 7; 8 Participants
Phase 2 N=15 Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
Sarcoidosis
Primary: Number of Participants Without Sarcoidosis Flare (Flare-Free Survival) — 2; 7 Participants
N/A N=7 Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement
Scleroderma, Systemic
Primary: Mean Change From Baseline in Forced Vital Capacity (FVC) — 0.1786 Liters — p=0.026
Phase 2 N=29 Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis
Alveolitis, Fibrosing · Fibrosis, Pulmonary · Hypertension, Pulmonary
Primary: Change in 6-minute Walk Test — -26; -7 meters
Phase 2 N=18 Inhaled GM-CSF Therapy of Autoimmune PAP
Autoimmune Pulmonary Alveolar Proteinosis
Primary: Time to Rescue WLL — 18; 30 Months — p=0.0078
Phase 2 N=51 Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
Scleroderma, Systemic · Interstitial Lung Disease
Primary: Percent Predicted Forced Vital Capacity (FVC-%) — 2.24; 2.09 percent predicted — p=0.9326
Phase 2 N=57 Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Systemic Sclerosis-Associated PAH
Primary: Change From Baseline in Distance Walked During a Six Minute Walk Test — 23.6; 0.5 Meters — p=0.12
N/A N=80 Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.
Interstitial Lung Disease · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Primary: Death From All Causes — 10; 5 Participants
Phase 2 N=35 Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
Albinism · Inborn Errors of Metabolism · Oculocutaneous Albinism
Primary: Change in Forced Vital Capacity (36 Months) — -23.52; -20.93 % of predicted volume
Phase 2 N=327 Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52 — -5.81; -5.24; -6.31 percent predicted FVC — p== 0.6339
Phase 2 N=2 Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
Hereditary Pulmonary Alveolar Proteinosis
Primary: Change in Time (Minutes) to Discontinuation of Exercise During a Standardized Treadmill Exercise Test — 17; 33 Percent Change
Phase 3 N=10 Rituximab in Rheumatoid Arthritis Lung Disease
Rheumatoid Arthritis · Interstitial Pneumonia
Primary: Change in Diffusion Capacity for Carbon Monoxide (DLco) From Baseline to 48 Weeks — 4; 2; 1 participants
Phase 3 N=236 Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
Pulmonary Fibrosis
Primary: Overall Change in Forced Vital Capacity — -0.18; -0.19 liters
Phase 3 N=180 Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis · Hypertension, Pulmonary
Primary: Change in 6-minute Walk Distance From Enrollment to Week 12 (≥ 20% Improvement) — 9; 6 participants — p=0.39